Hepatitis B Virus
European CHMP Issues Positive Opinion for Viread(R) for the Treatment of Chronic Hepatitis B
Published in AIDS Weekly, March 31st, 2008
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion on the company's application to extend the indication for Viread(R) (tenofovir disoproxil fumarate) to include the treatment of chronic hepatitis B in adults. The application, known as a Type II variation, was submitted to European regulatory authorities in October 2007.
The CHMP's positive opinion will be forwarded to the European Commission, which will amend the Marketing Authorisation for Viread in the 27 countries of the European Union to reflect the Type II variation. The European...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-03-31)
More Articles from AIDS Weekly
- HIV/AIDS
Researchers develop new tool to predict who will use microbicides - HIV/AIDS
UT-ORNL and UCSD researchers find promise in HIV 'switch' - HIV/AIDS
Data on HIV/AIDS discussed by C. Mihailidis and colleagues - HIV/AIDS
New HIV/AIDS research from S. Saengaroon et al outlined - HIV/AIDS
Study results from University of Paris update understanding of HIV/AIDS - HIV/AIDS Cancer
Studies in the area of HIV/AIDS cancer reported from University of Munich - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
